{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:32Z","timestamp":1761059132903},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,18]],"date-time":"2010-09-18T00:00:00Z","timestamp":1284768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00223-010-9417-5","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T00:21:12Z","timestamp":1284682872000},"page":"525-532","source":"Crossref","is-referenced-by-count":7,"title":["The Biphenyl-Carboxylate Derivative ABD328 is a Novel Orally Active Antiresorptive Agent"],"prefix":"10.1007","volume":"87","author":[{"given":"Aymen I.","family":"Idris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Coste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain R.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J.","family":"van\u2019t Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,18]]},"reference":[{"key":"9417_CR1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.2004.19.10.1651","volume":"19","author":"RJ van\u2019t Hof","year":"2004","unstructured":"van\u2019t Hof RJ, Idris AI, Ridge SA, Dunford J, Greig IR, Ralston SH (2004) Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J Bone Miner Res 19:1651\u20131660","journal-title":"J Bone Miner Res"},{"key":"9417_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/en.2008-0998","volume":"150","author":"AI Idris","year":"2009","unstructured":"Idris AI, Greig IR, Bassonga-Landao E, Ralston SH, van\u2019t Hof RJ (2009) Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation. Endocrinology 150:5\u201313","journal-title":"Endocrinology"},{"key":"9417_CR3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508\u20131514","journal-title":"Science"},{"key":"9417_CR4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"9417_CR5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226","journal-title":"N Engl J Med"},{"key":"9417_CR6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbrc.2008.04.014","volume":"371","author":"A Idris","year":"2008","unstructured":"Idris A, Mrak E, Greig I, Guidobono F, Ralston SH, van\u2019t Hof R (2008) ABD56 causes osteoclast apoptosis by inhibiting the NFkappaB and ERK pathways. Biochem Biophys Res Commun 371:94\u201398","journal-title":"Biochem Biophys Res Commun"},{"key":"9417_CR7","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1210\/en.2004-0205","volume":"145","author":"RJ van\u2019t Hof","year":"2004","unstructured":"van\u2019t Hof RJ, Macphee J, Libouban H, Helfrich MH, Ralston SH (2004) Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 145:5068\u20135074","journal-title":"Endocrinology"},{"key":"9417_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1385\/1-59259-366-6:145","volume-title":"Bone research protocols","author":"RJ van\u2019t Hof","year":"2003","unstructured":"van\u2019t Hof RJ (2003) Osteoclast formation in the mouse coculture assay. In: Helfrich MH, Ralston SH (eds) Bone research protocols. Humana Press, Totowa, NJ, pp 145\u2013152"},{"key":"9417_CR9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00223-004-0188-8","volume":"77","author":"TL Stewart","year":"2005","unstructured":"Stewart TL, Roschger P, Misof BM, Mann V, Fratzl P, Klaushofer K, Aspden RM, Ralston SH (2005) Association of COLIA1 Sp1 alleles with defective bone nodule formation in vitro and abnormal bone mineralisation in vivo. Calcif Tissue Int 77:113\u2013118","journal-title":"Calcif Tissue Int"},{"key":"9417_CR10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/8756-3282(95)00113-R","volume":"16","author":"PD Delmas","year":"1995","unstructured":"Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1\u201334) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate\u2014is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603\u2013610","journal-title":"Bone"},{"key":"9417_CR11","first-page":"53","volume":"1","author":"JA Gasser","year":"2000","unstructured":"Gasser JA, Kneissel M, Thomsen JS, Mosekilde L (2000) PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53\u201356","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"9417_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1359\/jbmr.060915","volume":"22","author":"R Samadfam","year":"2007","unstructured":"Samadfam R, Xia Q, Goltzman D (2007) Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55\u201363","journal-title":"J Bone Miner Res"},{"key":"9417_CR13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"9417_CR14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","volume":"82","author":"AI Idris","year":"2008","unstructured":"Idris AI, Rojas J, Greig IR, van\u2019t Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191\u2013201","journal-title":"Calcif Tissue Int"},{"key":"9417_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcb.21983","volume":"106","author":"IR Orriss","year":"2009","unstructured":"Orriss IR, Key ML, Colston KW, Arnett TR (2009) Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106:109\u2013118","journal-title":"J Cell Biochem"},{"key":"9417_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385","journal-title":"Bone"},{"key":"9417_CR17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.bone.2008.05.010","volume":"44","author":"H Yamane","year":"2009","unstructured":"Yamane H, Sakaia A, Moria T, Tanakaa S, Morideraa K, Nakamura T (2009) The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44:1055\u20131062","journal-title":"Bone"},{"key":"9417_CR18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJ Kostenuik","year":"2009","unstructured":"Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. J Bone Miner Res 24:182\u2013195","journal-title":"J Bone Miner Res"},{"key":"9417_CR19","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.1074\/jbc.M110.101964","volume":"285","author":"DD Pierroz","year":"2010","unstructured":"Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL (2010) Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH With denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 285:28164\u201328173","journal-title":"J Biol Chem"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-010-9417-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-010-9417-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-010-9417-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:37:59Z","timestamp":1558683479000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-010-9417-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,18]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9417"],"URL":"https:\/\/doi.org\/10.1007\/s00223-010-9417-5","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,18]]}}}